Medicalsystem Biotechnology Co., Ltd. (300439.SZ)
CNY 10.93
(1.3%)
CNY 10.93
(1.3%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 562.06 Million CNY | -19.25% |
| 2022 | 636.78 Million CNY | 3.48% |
| 2021 | 615.39 Million CNY | 6.15% |
| 2020 | 579.73 Million CNY | -17.25% |
| 2019 | 700.54 Million CNY | 9.33% |
| 2018 | 640.72 Million CNY | 17.56% |
| 2017 | 545 Million CNY | 51.02% |
| 2016 | 360.87 Million CNY | 60.49% |
| 2015 | 224.86 Million CNY | 38.43% |
| 2014 | 162.44 Million CNY | 36.3% |
| 2013 | 119.18 Million CNY | 47.71% |
| 2012 | 80.68 Million CNY | 67.91% |
| 2011 | 48.05 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 130.2 Million CNY | -13.23% |
| 2024 Q3 | 150.5 Million CNY | 1.5% |
| 2024 Q2 | 137.95 Million CNY | 5.95% |
| 2023 Q4 | 150.06 Million CNY | -10.12% |
| 2023 FY | 514.18 Million CNY | -19.25% |
| 2023 Q1 | 130.08 Million CNY | -26.14% |
| 2023 Q3 | 166.97 Million CNY | 19.09% |
| 2023 Q2 | 140.2 Million CNY | 7.78% |
| 2022 FY | 636.78 Million CNY | 3.48% |
| 2022 Q2 | 159.27 Million CNY | 20.21% |
| 2022 Q4 | 176.12 Million CNY | 4.29% |
| 2022 Q1 | 132.49 Million CNY | -16.71% |
| 2022 Q3 | 168.88 Million CNY | 6.04% |
| 2021 Q3 | 157.32 Million CNY | -1.38% |
| 2021 FY | 615.39 Million CNY | 6.15% |
| 2021 Q1 | 139.46 Million CNY | 0.0% |
| 2021 Q2 | 159.52 Million CNY | 14.39% |
| 2021 Q4 | 159.08 Million CNY | 1.12% |
| 2020 Q4 | 139.45 Million CNY | -14.62% |
| 2020 Q3 | 163.33 Million CNY | 7.12% |
| 2020 FY | 579.73 Million CNY | -17.25% |
| 2020 Q1 | 124.45 Million CNY | -40.61% |
| 2020 Q2 | 152.48 Million CNY | 22.52% |
| 2019 Q3 | 190.12 Million CNY | 30.73% |
| 2019 FY | 700.54 Million CNY | 9.33% |
| 2019 Q4 | 209.56 Million CNY | 10.22% |
| 2019 Q2 | 145.43 Million CNY | -6.42% |
| 2019 Q1 | 155.41 Million CNY | -15.41% |
| 2018 Q1 | 134.73 Million CNY | -26.38% |
| 2018 Q4 | 183.74 Million CNY | 7.45% |
| 2018 Q2 | 151.26 Million CNY | 12.27% |
| 2018 Q3 | 170.99 Million CNY | 13.05% |
| 2018 FY | 640.72 Million CNY | 17.56% |
| 2017 Q3 | 129.38 Million CNY | 8.0% |
| 2017 FY | 545 Million CNY | 51.02% |
| 2017 Q1 | 112.8 Million CNY | -8.69% |
| 2017 Q2 | 119.8 Million CNY | 6.21% |
| 2017 Q4 | 183.01 Million CNY | 41.44% |
| 2016 Q3 | 89.13 Million CNY | 19.0% |
| 2016 FY | 360.87 Million CNY | 60.49% |
| 2016 Q2 | 74.9 Million CNY | 2.2% |
| 2016 Q1 | 73.29 Million CNY | 50.04% |
| 2016 Q4 | 123.53 Million CNY | 38.59% |
| 2015 Q1 | 51.73 Million CNY | 0.4% |
| 2015 Q4 | 48.84 Million CNY | -24.67% |
| 2015 Q3 | 64.84 Million CNY | 9.11% |
| 2015 Q2 | 59.43 Million CNY | 14.88% |
| 2015 FY | 224.86 Million CNY | 38.43% |
| 2014 FY | 162.44 Million CNY | 36.3% |
| 2014 Q3 | 40.71 Million CNY | 10.27% |
| 2014 Q4 | 51.53 Million CNY | 26.57% |
| 2014 Q1 | 33.27 Million CNY | 0.0% |
| 2014 Q2 | 36.92 Million CNY | 10.95% |
| 2013 FY | 119.18 Million CNY | 47.71% |
| 2012 FY | 80.68 Million CNY | 67.91% |
| 2011 FY | 48.05 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 3.35 Billion CNY | 83.236% |
| Hangzhou Tigermed Consulting Co., Ltd. | 358.41 Million CNY | -56.819% |
| Dirui Industrial Co.,Ltd. | 387.16 Million CNY | -45.175% |
| Beijing Strong Biotechnologies, Inc. | 702.74 Million CNY | 20.019% |
| Maccura Biotechnology Co.Ltd | 1.18 Billion CNY | 52.384% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.17 Billion CNY | 52.181% |
| Guangdong Hybribio Biotech Co.,Ltd. | 631.43 Million CNY | 10.987% |
| BGI Genomics Co., Ltd. | 1.93 Billion CNY | 71.017% |
| Amoy Diagnostics Co., Ltd. | 574.96 Million CNY | 2.244% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 479.96 Million CNY | -17.104% |